Market Cap : 1.86 B | Enterprise Value : 24.01 B | PE Ratio : At Loss | PB Ratio : |
---|
NYSE:BHC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:BHC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Bausch Health has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.
Warning Sign:
Bausch Health Companies Inc displays poor financial strength. Usually, this is caused by too much debt for the company.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.Bausch Health's Interest Coverage for the quarter that ended in Mar. 2022 was 0.85. Bausch Health's debt to revenue ratio for the quarter that ended in Mar. 2022 was 3.02. As of today, Bausch Health's Altman Z-Score is 0.04.
For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Financial Strength distribution charts can be found below:
* The bar in red indicates where Bausch Health's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Bausch Health's Interest Expense for the months ended in Mar. 2022 was $-362 Mil. Its Operating Income for the months ended in Mar. 2022 was $308 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $23,168 Mil.
Bausch Health's Interest Coverage for the quarter that ended in Mar. 2022 is
Interest Coverage | = | -1 | * | Operating Income (Q: Mar. 2022 ) | / | Interest Expense (Q: Mar. 2022 ) |
= | -1 | * | 308 | / | -362 | |
= | 0.85 |
The higher the ratio, the stronger the company's financial strength is.
Warning Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Bausch Health Companies Incs earnings cannot cover its interest expense. If the situation continues, the company may have to issue more debt.
2. Debt to revenue ratio. The lower, the better.
Bausch Health's Debt to Revenue Ratio for the quarter that ended in Mar. 2022 is
Debt to Revenue Ratio | = | Total Debt (Q: Mar. 2022 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (0 | + | 23168) | / | 7672 | |
= | 3.02 |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Bausch Health has a Z-score of 0.04, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of 0.04 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
Bausch Health has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.
Thank you for viewing the detailed overview of Bausch Health's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Carson Seana | officer: EVP, General Counsel | 400 SOMERSET CORPORATE BLVD BRIDGEWATER NJ 08807 |
Vadaketh Tom George | officer: EVP, Chief Financial Officer | 1727 JOCKEYS WAY YARDLEY PA 19067 |
Mulligan Richard | director | C/O ICAHN CAPITAL LP 767 FIFTH AVENUE, SUITE 4700 NEW YORK NY 10153 |
Munsch Frederick | officer: SVP, Controller and CAO | 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Gordon Joseph F | officer: Pres&Co-Head Bausch&Lomb/Int'l | 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Ackermann Christina | officer: EVP AND GENERAL COUNSEL | C/O BLCO 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Spurr Robert | director, officer: U.S. President-Pharma Business | C/O BAUSCH HEALTH COMPANIES INC. 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Eldessouky Sam | officer: EVP & Chief Financial Officer | C/O BAUSCH HEALTH COMPANIES INC. 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Miller Steven D | director | 16690 COLLINS AVENUE PH SUNNY ISLE BEACH FL 33160 |
Icahn Brett | director | C/O ICAHN ENTERPRISES L.P. 16690 COLLINS AVE., PH SUNNY ISLES FL 33160 |
Paulson John | director | 1133 AVENUE OF THE AMERICAS 33RD FLOOR NEW YORK NY 10036 |
Valueact Holdings Ii, L.p. | director, other: See Remarks | ONE LETTERMAN DRIVE BUILDING D, FOURTH FLOOR SAN FRANCISCO CA 94129 |
Von Eschenbach Andrew C. | director | BAUSCH HEALTH COMPANIES INC. 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Mckenna Mark C. | officer: President, Salix | 400 SOMERSET CORPORATE BOULEVARD BRIDGEWATER NJ 08807 |
Humphries William D. | officer: EVP, COMPANY GROUP CHAIRMAN | C/O STRATA SKIN SCIENCES, INC. 5 WALNUT GROVE DRIVE SUITE 140 HORSHAM PA 19044 |
Other Sources
By Zacks 2022-03-25
By Zacks 2022-02-24
By Zacks 2022-01-31
By Zacks 2022-01-19
By Zacks 2022-02-23
By Zacks 2022-02-22
By Zacks 2022-01-31
By Seekingalpha 2022-02-23
By Zacks 2022-03-10
By Zacks 2022-02-21
By Seekingalpha 2022-01-31
By Zacks 2022-01-14
By Zacks 2022-03-15